Skip to Content

Enalapril / hydrochlorothiazide Side Effects

Not all side effects for enalapril / hydrochlorothiazide may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to enalapril / hydrochlorothiazide: oral tablet

In addition to its needed effects, some unwanted effects may be caused by enalapril / hydrochlorothiazide. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking enalapril / hydrochlorothiazide:

Less common
  • Blurred vision
  • chest pain or discomfort
  • chills
  • cold sweats
  • coma
  • confusion
  • decreased urine output
  • diarrhea
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • drowsiness
  • dry mouth
  • fainting
  • fast, slow, or irregular heartbeat
  • headache
  • increased thirst
  • irritability
  • loss of appetite
  • muscle pain or cramps
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • rapid breathing
  • seizures
  • shortness of breath
  • sunken eyes
  • sweating
  • swelling of the face, ankles, or hands
  • thirst
  • unusual tiredness or weakness
  • weak pulse
  • wrinkled skin

Some of the side effects that can occur with enalapril / hydrochlorothiazide may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Cough
  • decreased interest in sexual intercourse
  • inability to have or keep an erection
  • lack or loss of strength
  • loss in sexual ability, desire, drive, or performance

For Healthcare Professionals

Applies to enalapril / hydrochlorothiazide: oral tablet


Predisposing risk factors for hypotension after enalapril-HCTZ administration are decreased intravascular volume (angiotensin-dependency) and hyponatremia.[Ref]

Cardiovascular complications are among the most common. Hypotension occurs in approximately 2% to 8%, and is more common in patients with hypovolemia. This can result in syncope in 1% to 4% of patients. Hypokalemia associated with hydrochlorothiazide (HCTZ) monotherapy has been associated with rare cases of cardiac arrhythmias, including ventricular ectopy and complete AV heart block. Chest pain has been reported in up to 5% of patients who are receiving enalapril.[Ref]


Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%, and may reduce insulin secretion, it should be used with caution in diabetic patients and in those with hypercholesterolemia. Indeed, rare cases of hyperosmolar hyperglycemic coma are associated with HCTZ.

Hyperuricemia may be an important consideration in patients with a history of gout. Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.[Ref]

Metabolic side effects, such as hypokalemia, hyponatremia, hypomagnesemia, and hyperuricemia are common during HCTZ therapy, especially when doses greater than 50 mg per day are used. Mild hypokalemia (decrease of 0.5 mEq/L) occurs in up to 50% of patients taking HCTZ alone; this is less likely with the combination drug because enalapril attenuates the aldosteronism associated with thiazide diuretics. Metabolic alkalosis, hypercalcemia, hyperglycemia, and hypercholesterolemia have been associated with the use of HCTZ.[Ref]


Renal side effects including renal insufficiency has been associated with both the use of enalapril and HCTZ, and is, therefore, a problem with the combination product. Enalapril-associated renal failure is more likely in patients with "high angiotensin states" (congestive heart failure, edema, renal artery stenosis, hypovolemia, hypotension, or chronic renal failure). Rare cases of interstitial nephritis have been associated with HCTZ.[Ref]

Enalapril, like other angiotensin converting enzyme inhibitors, may decrease serum aldosterone levels, resulting in mild to moderate hyperkalemia.

Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case report in which the drug was believed to have caused this condition is reported.[Ref]


Hepatic side effects associated with the use of ACE inhibitors have included a rare syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. Experts recommend discontinuation of therapy with this drug if jaundice or markedly elevated hepatic serum enzymes develop. Both cholestatic jaundice and centrilobular necrosis have been described.[Ref]

Rare case reports of enalapril-associated hepatitis, where liver function tests rose despite resolution of congestive heart failure, are reported.

A 54-year-old woman with hypertension developed asymptomatic abnormal liver function tests associated with eosinophilia and relatively normal abdominal ultrasonography seven weeks after beginning enalapril. An extensive work-up revealed no evidence of infection; liver biopsy revealed cellular degeneration, portal eosinophilic and mononuclear infiltration, and centrilobular necrosis. The signs and symptoms of hepatitis resolved upon discontinuation of enalapril.[Ref]


Late-onset enalapril-induced angioedema (more than three months) is reported in at least one patient who had taken enalapril without incident for three years. Patients with intestinal angioedema generally present with abdominal pain (with or without nausea or vomiting) and in some cases there was no prior history of facial angioedema, and C-1 esterase levels were normal. These symptoms resolve after stopping the ACE inhibitor.

A 68-year-old man with a history of myocardial infarction (MI) developed dyspnea, chest tightness, a low grade fever, dizziness, sweating, and vomiting associated with cyanosis, a mild leukocytosis, radiographic evidence of pulmonary edema, clinical evidence of hypovolemia, and respiratory acidosis. MI and infection were ruled out; the patient recovered after restoration of his intravascular volume with saline and albumin. The only precipitating factor per history was taking HCTZ, which the patient had taken without incident for two years. Rechallenge with the drug resulted in recurrent acute pulmonary edema. Other signs of hypersensitivity, such as rash and eosinophilia, were absent.[Ref]

Hypersensitivity reactions to enalapril, as with some other angiotensin converting enzyme (ACE) inhibitors, may be life-threatening. Angioedema of the face, extremities, lips, tongue, glottis and/or pharynx have been reported rarely in patients receiving ACE inhibitors. Obstructive laryngeal and glossal angioedema due to enalapril is a rare, but potentially fatal reaction. In addition, intestinal angioedema has been reported in patients treated with ACE inhibitors. It is recommended that any patient with dyspnea, dysphagia, or significant facial angioedema stop therapy immediately and avoid ACE inhibitor therapy in general. Enalapril is not recommended for patients with a history of idiopathic angioedema.

Other hypersensitivity reactions associated with enalapril including photosensitivity in 0.1%, or urticaria in 0.3% of patients have been reported. A single case of Henoch-Schonlein purpura has also been reported.

Rare cases of acute pulmonary edema, interstitial cystitis, interstitial nephritis, and anaphylaxis have been associated with HCTZ.[Ref]


Respiratory system side effects are remarkable for a dry, nonproductive cough that has usually become a problem for 1% to 5% of patients who are receiving enalapril alone. Some patients with enalapril-induced cough demonstrate new bronchial hyper-reactivity. Less common respiratory system side effects include rhinorrhea associated with enalapril (thought to be due to the effect of enalapril on vasodilating kinins) and approximately 30 case reports of acute noncardiogenic pulmonary edema associated with HCTZ (thought to be due to idiosyncrasy or a hypersensitivity mechanism).[Ref]

Rare case reports of asthma associated with some angiotensin converting enzyme inhibitors suggest that these drugs seem to play a role in the genesis and metabolism of bronchodilatory mediators. For this reason, some experts recommend cautious use of enalapril in patients with preexisting asthma.

A retrospective study has revealed a significantly higher incidence of discontinuation of angiotensin converting enzyme inhibitor therapy due to cough among black patients compared with non-black patients (9.6% vs. 2.4%).[Ref]


Hematologic side effects are extremely rare with either drug. Discontinuation of enalapril due to anemia has been reported in less than 0.1% of patients. Rare cases of neutropenia and agranulocytosis have been associated with enalapril and rare cases of immune-complex hemolytic anemia, aplastic anemia, and thrombocytopenia have been associated with HCTZ.[Ref]

An 83-year-old woman with a history of hypertension, angina pectoris, coronary artery disease, and myocardial infarction developed fever associated with profound neutropenia and an E. coli urinary tract infection six months after beginning enalapril. Bone marrow aspiration revealed only a few myeloid progenitors, but normal erythropoiesis and megakaryocytic differentiation. The agranulocytosis resolved once enalapril was discontinued.[Ref]

Nervous system

Nervous system side effects including headache is the most common. Headache occurs in 3% to 12% of patients. Other nervous system complaints, such as vertigo, fatigue, paresthesias, and insomnia have only rarely been reported. A single case of cerebrovascular insufficiency has been associated with HCTZ-induced plasma volume contraction.[Ref]


Dermatologic side effects have been associated with the use of both ACE inhibitors and thiazide diuretics. Thiazides may induce phototoxic dermatitis. In addition, a rare, distinct entity with clinical and laboratory features indistinguishable from those of subacute cutaneous lupus erythematosus has been associated with HCTZ. Other dermatologic reactions include rare reports of erythema annular centrifugum, acute eczematous dermatitis, morbilliform and leukocytoclastic vasculitis associated with HCTZ, and alopecia, photosensitive lichenoid eruptions, erythema with vasculitis, bullous pemphigoid, and pemphigus foliaceus associated with enalapril.[Ref]

A 52-year-old Korean woman with hypertension experienced a generalized, erythematous, scaly rash associated with a positive Nikolsky sign and biopsy results consistent with pemphigus foliaceus within three weeks after beginning enalapril. Direct immunofluorescence revealed intercellular IgG deposition. The pemphigus remained active at least 12 months after enalapril was discontinued.

A 67-year-old white woman with hypothyroidism, hypercalcemia, depression, and hypertension developed facial erythema, headaches, tremors, confusion, and personality changes associated with a new positive ANA and anti-nRNP, and skin biopsy consistent with lupus erythematosus while taking HCTZ, levothyroxine, and amitriptyline. The eruption resolved upon discontinuation of HCTZ, but she later developed a higher ANA titer associated with symptomatic diffuse interstitial pulmonary infiltrates. She was successfully treated with corticosteroids.

A 35-year-old woman with hypertension developed alopecia during enalapril therapy, which resolved upon discontinuation of the drug, and recurred upon rechallenge.[Ref]


A 56-year-old woman with hypertension and diabetes developed acute abdominal pain, nausea, and vomiting associated upper abdominal tenderness, hyperamylasemia, hyperlipasemia, and normal upper abdominal ultrasonography within 24 hours of starting enalapril. The signs and symptoms of pancreatitis resolved over the next several days once the drug was discontinued. No rechallenge was performed.

Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in increased risk of cholesterol gallstone formation. Reports of bowel strictures associated with thiazide ingestion have been reported in the 1960's, although these patients were on a combination HCTZ-potassium product.[Ref]

Gastrointestinal side effects are unusual. Nausea, vomiting, or diarrhea have each been reported in less than 3% of patients who are receiving enalapril. Dysgeusia is rare, occurring in less than 0.5% of patients. Rare cases of acute small bowel mucosal edema, acute cholecystitis, or pancreatitis have been associated with either drug.[Ref]


There are rare case reports of HCTZ-induced immune hemolytic anemia. The following illustrates a fatal case:

A 53-year-old man with hypertension developed nausea, vomiting, diarrhea, and progressive anorexia and weakness associated with scleral icterus, anemia with spherocytosis, dark red urine with proteinuria, bilirubinuria, hemoglobinuria, and elevated lactic dehydrogenase levels 18 months after beginning HCTZ and methyldopa. Haptoglobin was less than 50 mg/dl. Direct and indirect Coombs' tests were positive. The patient died suddenly; autopsy revealed no obvious cause of death, left ventricular hypertrophy, and mild coronary atherosclerosis.[Ref]

Immunologic side effects have been reported in a limited study of nine elderly patients, three of whom developed a positive fluorescent antinuclear antibody test during six weeks of enalapril therapy. Allergic vasculitis and hemolytic anemia have rarely been associated with HCTZ.[Ref]


A 76-year-old woman with hypertension, on enalapril monotherapy for three weeks, developed progressive myalgias, asthenia, morning stiffness, and weakness associated with no abnormal laboratory values. Due to the absence of other apparent causes, enalapril was discontinued, and the patient's myalgias disappeared.[Ref]

Musculoskeletal side effects are unusual and include case reports of myalgias and chills.[Ref]


Endocrinologic problems associated with thiazide diuretics include glucose intolerance and a potentially deleterious effect on the lipid profile. This may be important in some patients with or who are at risk for diabetes or coronary artery disease. A single case of recurrent parathyroid adenoma has been reported, although the association is probably coincidental. The only reported endocrinologic side effects associated with the use of enalapril include one case of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and three cases of glycosuria.[Ref]

A 69-year-old woman with diabetes mellitus and hypertension developed symptomatic hyponatremia associated with decreased plasma and increased urine osmolalities, normal thyroid and basal cortisol studies, and a positive water load test four months after beginning enalapril. The syndrome resolved upon discontinuation of enalapril, and recurred upon rechallenge.

A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed an increased mean fasting blood glucose level after treatment. Withdrawal of thiazide therapy for seven months in 10 of the patients resulted in average reductions of 10% in fasting blood glucose and 25% in the 2-hour glucose tolerance test value. A control group was not reported.[Ref]


A 52-year-old woman with hypertension and a history of depression associated with the use of beta-blockers, developed fatigue, malaise, and clinical signs and symptoms of depression, including suicidal ideation, within five weeks after starting enalapril. The depression gradually resolved with substitution of a thiazide diuretic and a low sodium diet. Rechallenge resulted in recurrent depression.

A 41-year-old man with hypertension became agitated, anxious, depressed, and unable to sleep four weeks after starting enalapril. The psychosis resolved when enalapril was stopped, and recurred upon rechallenge.[Ref]

Psychiatric problems associated with the use of enalapril include rare cases of depression and acute psychosis.[Ref]


Genitourinary side effects including rare reports of vulvovaginal pruritus, dysuria, and incontinence have been associated with the use of enalapril in an elderly patient.[Ref]


Ocular side effects have included idiosyncratic reactions to the hydrochlorothiazide component resulting in acute transient myopia and acute angle-closure glaucoma.


1. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988): 380-5

2. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991): 165-8

3. Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987): 143-8

4. Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981): 67-73

5. Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989): 837-8

6. Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990): 312-3

7. Inman WH, Rawson NS, Wilton LV, et al "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988): 826-9

8. Todd PA, Goa KL "Enalapril: a reappraisal of its pharmacology and therapeutic use in hypertension." Drugs 43 (1992): 346-81

9. Cooper WD, Sheldon D, Brown D, et al "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987): 346-9

10. Eisner GM, Johnson BF, McMahon FG, et al "A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension." Am J Hypertens 4 (1991): s154-7

11. Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990): 1287-9

12. Fagher B, Katzman P, Hulthen UL, et al "Antihypertensive efficacy and tolerability of enalapril and slow-release verapamil in essential hypertension: a double-blind, cross-over study." J Intern Med 230 (1991): 219-26

13. Francis GS, Rucinska EJ "Long-term effects of a once-a-day versus twice-a-day regimen of enalapril for congestive heart failure." Am J Cardiol 63 (1989): d17-21

14. Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991): 555-8

15. Bajaj AK "Topics in clinical pharmacology: enalapril, a second-generation angiotensin converting enzyme inhibitor." Am J Med Sci 296 (1988): 332-5

16. Todd PA, Heel RC "Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure." Drugs 31 (1986): 198-248

17. Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983): 1017-22

18. Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 48

19. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,

20. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5

21. Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986): 341

22. Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990): 739-42

23. Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860

24. Luccioni R, Sever PS, Diperri T, Redon J, Laurandin I, Brault Y, Chastang C, Guez D, Andrejak M, Araud JM, Aupy JM, Baclet J "An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension." J Hypertens 13 (1995): 1847-51

25. Ross H, Moser M "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 859-60

26. Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981): 80-3

27. Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986): 634

28. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983): 283-96

29. Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 175-6

30. Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990): 704-8

31. Hume AL, Murphy JL, Lauerman SE "Angiotensin-converting enzyme inhibitor-induced cough." Pharmacotherapy 9 (1989): 88-90

32. Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990): 66-9

33. Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985): 337-43

34. Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992): 479-87

35. O'Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988): 525-7

36. Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993): 25-7

37. Schwartz D, Averbuch M, Pines A, et al "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991): 1558-61

38. Rosellini SR, Costa PL, Gaudio M, et al "Hepatic injury related to enalapril ." Gastroenterology 97 (1989): 810

39. Shionoiri H, Nomura S, Oda H, et al "Hepatitis associated with captopril and enalapril but not with delapril in a patient with congestive heart failure receiving chronic hemodialysis." Curr Ther Res Clin Exp 42 (1987): 1171-6

40. Todd P, Levison D, Farthing MJ "Enalapril-related cholestatic jaundice." J R Soc Med 83 (1990): 271-2

41. Kitai E, Sandiuk A, Zalewski S "Enalapril-induced immunologic impairment of hepatic function." J Fam Pract 33 (1991): 301-2

42. Gianos ME, Klaustermeyer WB, Kurohara M, et al "Enalapril induced angioedema." Am J Emerg Med 8 (1990): 124-6

43. Moots RJ,Keeling PJ, Morgan SH "Adult schonlein-henoch purpura after enalapril." Lancet 340 (1992): 304-5

44. Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990): 1156-60

45. Biron P, Dessureault J, Napke E "Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]." Can Med Assoc J 145 (1991): 28-34

46. Hoss DM, Nierenberg DW "Severe shaking chills and fever following hydrochlorothiazide administration." Am J Med 85 (1988): 747

47. Dorn MR, Walker BK "Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy." Chest 79 (1981): 482-3

48. Levay ID "Hydrochlorothiazide-induced pulmonary edema." Drug Intell Clin Pharm 18 (1984): 238-9

49. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A "Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide ." Intensive Care Med 13 (1987): 364-5

50. Hoegholm A, Rasmussen SW, Kristensen KS "Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction." Br Heart J 63 (1990): 186

51. Jain M, Armstrong L, Hall J "Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy." Chest 102 (1992): 871-4

52. Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991): 1059

53. Grace AA, Morgan AD, Strickland NH "Hydrochlorothiazide causing unexplained pulmonary oedema." Br J Clin Pract 43 (1989): 79-81

54. Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990): 566-8

55. Klein MD "Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion." Ann Emerg Med 16 (1987): 901-3

56. Cichelli AV, Lenchner GS, Promisloff RA, Segal SL "Enalapril-induced cough ." Am J Med 83 (1987): 1009-10

57. Elliott WJ "Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects." Clin Pharmacol Ther 60 (1996): 582-8

58. Guul SJ, Os I, Jounela AJ "The efficacy and tolerability of enalapril in a formulation with a very low dose of hydrochlorothiazide in hypertensive patients resistent to enalapril monotherapy." Am J Hypertens 8 (1995): 727-31

59. Lindgren BR, Rosenqvist U, Ekstrom T, et al "Increased bronchial reactivity and potentiated skin responses in hypertensive subjects suffering from coughs during ACE-inhibitor therapy." Chest 95 (1989): 1225-30

60. Fennerty A, Littley M, Reid P "Enalapril-induced nasal blockage ." Lancet 2 (1986): 1395-6

61. McEwan JR, Choudry N, Street R, Fuller RW "Change in cough reflex after treatment with enalapril and ramipril." Br Med J 299 (1989): 13-6

62. Mue S, Tamura G, Yamauchi K, et al "Bronchial responses to enalapril in asthmatic, hypertensive patients." Clin Ther 12 (1990): 335-43

63. Roth A "Chronic cough caused by angiotensin converting enzyme inhibitors." Ann Allergy 64 (1990): 47-8

64. Kaufman J, Casanova JE, Riendl P, Schlueter DP "Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors." Chest 95 (1989): 544-8

65. Semple PF, Herd GW "Cough and wheeze caused by inhibitors of angiotensin-converting enzyme ." N Engl J Med 314 (1986): 61

66. Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991): 461-2

67. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991): 199-205

68. Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988): 209-10

69. Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984): 23-35

70. Hormigo A, Alves M "Peripheral neuropathy in a patient receiving enalapril." Br Med J 305 (1992): 1332

71. Smith EP, Taylor TB, Meyer LJ, Zone JJ "Antigen identification in drug-induced bullous pemphigoid." J Am Acad Dermatol 29 (1993): 879-82

72. Carrington PR, Sanusi ID, Zahradka S, Winder PR "Enalapril-associated erythema and vasculitis." Cutis 51 (1993): 121-3

73. Ahmad S "Enalapril and reversible alopecia ." Arch Intern Med 151 (1991): 404

74. Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993): 1001-2

75. Kanwar AJ, Dhar S, Ghosh S "Photosensitive lichenoid eruption due to enalapril." Dermatology 187 (1993): 80

76. Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989): 100-2

77. Shelton RM "Pemphigus foliaceus associated with enalapril." J Am Acad Dermatol 24 (1991): 503-4

78. Diffey BL, Langtry J "Phototoxic potential of thiazide diuretics in normal subjects." Arch Dermatol 125 (1989): 1355-8

79. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8

80. Firth NA, Reade PC "Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions." Oral Surg Oral Med Oral Pathol 67 (1989): 41-4

81. Farraye FA, Peppercorn MA, Steer ML, et al "Acute small-bowel mucosal edema following enalapril use ." JAMA 259 (1988): 3131

82. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101

83. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11

84. Schwartz D, Pines A, Averbuch M, Levo Y "Enalapril-induced antinuclear antibodies ." Lancet 336 (1990): 187

85. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM "Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia." Transfusion 28 (1988): 70-2

86. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW "Fatal intravascular immune hemolysis induced by hydrochlorothiazide." Am J Clin Pathol 81 (1984): 791-4

87. Peppers MP "Myalgia and arthralgia associated with enalapril and ramipril." Am J Health Syst Pharm 52 (1995): 203-4

88. Leloet X, Moore N, Deshayes P "Pseudopolymyalgia rheumatica during treatment with enalapril." Br Med J 298 (1989): 325

89. Milavetz JJ, Popovtzer MM "Angiotensin-converting enzyme inhibitors and glycosuria." Arch Intern Med 152 (1992): 1081-3

90. Castrillon JL, Mediavilla A, Mendez MA, et al "Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and enalapril." J Intern Med 233 (1993): 89-91

91. Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973): 1238-9

92. Patterson JF "Depression associated with enalapril." South Med J 82 (1989): 402-3

93. Ahmad S "Enalapril-induced acute psychosis ." Drug Intell Clin Pharm 25 (1991): 558-9

94. Casanova JE "Incontinence after use of enalapril ." J Urol 143 (1990): 1237-8

95. Heckerling PS "Enalapril and vulvovaginal pruritis ." Ann Intern Med 112 (1990): 879-80

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.